StockData
ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW

Estrella Immunopharma, Inc.

Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.38−0.05 (-11.65%)

Close on Oct 19, 2026

Market cap
$16.17M
P/E (TTM)
–
Dividend yield
–

Estrella Immunopharma, Inc. revenue by segment

No segment breakdown reported

Estrella Immunopharma does not break out revenue by segment, region or product in the tagged data of its filings for this period type.